The following Structured Product Label (SPL) was submitted to the FDA by Cephalon, Llc for the product Granix (NDC 63459-912). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.
This specific version of the label includes detailed information regarding 1 indications and usage, 2.1 dosage, 2.2 general considerations for administration, 2.3 instructions for use of the safety needle guard device by healthcare professionals, 3 dosage forms and strengths, 4 contraindications, 5.1 splenic rupture, 5.2 acute respiratory distress syndrome (ards), and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.
GRANIX is indicated to reduce the duration of severe neutropenia in patients with non‑myeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a clinically significant incidence of febrile neutropenia.
The recommended dose of GRANIX is 5 mcg/kg per day administered as a subcutaneous injection. Administer the first dose of GRANIX no earlier than 24 hours following myelosuppressive chemotherapy. Do not administer GRANIX within 24 hours prior to chemotherapy.
Daily dosing with GRANIX should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range. Monitor complete blood count (CBC) prior to chemotherapy and twice per week until recovery.
GRANIX may be administered by either a healthcare professional or by a patient or caregiver. Before a decision is made to allow GRANIX to be administered by a patient or caregiver, ensure that the patient is an appropriate candidate for self-administration or administration by a caregiver. Proper training on storage, preparation, and administration technique should be provided. If a patient or caregiver is not an appropriate candidate for any reason, then in such patients, GRANIX should be administered by a healthcare professional.
Dispense only the pre-filled syringe without a safety needle guard device to patient or caregiver. Instruct patients and caregivers to follow the Instructions for Use provided with the GRANIX pre-filled syringe to properly administer an injection after training by a healthcare professional.
Visually inspect parenteral drug products for particulate matter and discoloration prior to administration. Do not administer GRANIX if discoloration or particulates are observed.
The prefilled syringe is for single-dose only. Discard unused portions. GRANIX and all its components are not made with natural rubber latex.
Recommended sites for subcutaneous GRANIX injections include the abdomen (except for the two-inch area around the navel), the front of the middle thighs, the upper outer areas of the buttocks, or the upper back portion of the upper arms. The injection site should be varied daily. GRANIX should not be injected into an area that is tender, red, bruised or hard, or that has scars or stretch marks.
Hold the syringe assembly by the open sides of the device and remove the needle shield.
Expel any extra volume depending on dose needed.
Inject GRANIX subcutaneously as recommended [see Dosage and Administration (2.2)].
Push the plunger as far as it will go to inject all the medication. Injection of the entire prefilled syringe contents is necessary to activate the needle guard.
With the plunger still pressed all the way down, remove the needle from the skin.
Slowly let go of the plunger and allow the empty syringe to move up inside the device until the entire needle is guarded.
Discard the syringe assembly in approved containers.
Injection: 300 mcg/0.5 mL solution in single-dose prefilled syringe
Injection: 480 mcg/0.8 mL solution in single-dose prefilled syringe
GRANIX is contraindicated in patients with a history of serious allergic reactions to filgrastim or pegfilgrastim products [see Warnings and Precautions (5.3)].
Splenic rupture, including fatal cases, can occur following administration of filgrastim products. In patients who report upper abdominal or shoulder pain after receiving GRANIX, discontinue GRANIX and evaluate for an enlarged spleen or splenic rupture.
Acute respiratory distress syndrome (ARDS) can occur in patients receiving filgrastim products. Evaluate patients who develop fever and lung infiltrates or respiratory distress after receiving GRANIX, for ARDS. Discontinue GRANIX in patients with ARDS.
Serious allergic reactions, including anaphylaxis, can occur in patients receiving GRANIX. Reactions can occur on initial exposure. The administration of antihistamines‚ steroids‚ bronchodilators‚ and/or epinephrine may reduce the severity of the reactions. Permanently discontinue GRANIX in patients with serious allergic reactions. Do not administer GRANIX to patients with a history of serious allergic reactions to filgrastim or pegfilgrastim.
Severe and sometimes fatal sickle cell crises can occur in patients with sickle cell disease receiving filgrastim products. Consider the potential risks and benefits prior to the administration of GRANIX in patients with sickle cell disease. Discontinue GRANIX in patients undergoing a sickle cell crisis.
Glomerulonephritis can occur in patients receiving filgrastim products. The diagnoses were based on azotemia, hematuria (microscopic and macroscopic), proteinuria, and renal biopsy. Generally, events of glomerulonephritis resolved after dose reduction or discontinuation of the filgrastim product. If glomerulonephritis is suspected, evaluate for cause. If causality is likely, consider dose-reduction or interruption of GRANIX.
Capillary leak syndrome (CLS) can occur in patients receiving filgrastim products and is characterized by hypotension, hypoalbuminemia, edema and hemoconcentration. Episodes vary in frequency, severity and may be life-threatening if treatment is delayed. Patients who develop symptoms of capillary leak syndrome should be closely monitored and receive standard symptomatic treatment, which may include a need for intensive care.
The granulocyte colony-stimulating factor (G‑CSF) receptor through which GRANIX acts has been found on tumor cell lines. The possibility that GRANIX acts as a growth factor for any tumor type, including myeloid malignancies and myelodysplasia, diseases for which GRANIX is not approved, cannot be excluded.
The following potential serious adverse reactions are discussed in greater detail in other sections of the labeling:
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
GRANIX clinical trials safety data are based upon the results of three randomized clinical trials in patients receiving myeloablative chemotherapy for breast cancer (N=348), lung cancer (N=240) and non-Hodgkin’s lymphoma (N=92). In the breast cancer study, 99% of patients were female, the median age was 50 years, and 86% of patients were Caucasian. In the lung cancer study, 80% of patients were male, the median age was 58 years, and 95% of patients were Caucasian. In the non-Hodgkin’s lymphoma study, 52% of patients were male, the median age was 55 years, and 88% of patients were Caucasian. In all three studies a placebo (Cycle 1 of the breast cancer study only) or a non-US-approved filgrastim product were used as controls. Both GRANIX and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 106/L after nadir was reached.
Bone pain was the most frequent treatment-emergent adverse reaction that occurred in at least 1% or greater in patients treated with GRANIX at the recommended dose and was numerically two times more frequent than in the placebo group. The overall incidence of bone pain in Cycle 1 of treatment was 3.4% (3.4% GRANIX, 1.4% placebo, 7.5% non-US-approved filgrastim product).
Leukocytosis
In clinical studies, leukocytosis (WBC counts > 100,000 x 106/L) was observed in less than 1% patients with non-myeloid malignancies receiving GRANIX. No complications attributable to leukocytosis were reported in clinical studies.
Additional Adverse Reactions
Other adverse reactions known to occur following administration of filgrastim products include myalgia, headache, vomiting, cutaneous vasculitis and thrombocytopenia.
As with all therapeutic proteins, there is a potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay, and the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to GRANIX with the incidence of antibodies to other products may be misleading.
Binding antibodies to GRANIX were detected using a validated bridging immunoassay. In three clinical trials in oncology patients receiving prior chemotherapy, the incidence of antibody binding to tbo-filgrastim was 1.6 % (7/436). None of these 7 patients had cross-reactive antibodies to the native G-CSF. All antibody responses were transient and of low titers.
The following adverse reactions have been identified during post-approval use of GRANIX. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Sweet’s syndrome (acute febrile neutrophilic dermatosis), asthenia, diarrhea, and fatigue
No formal drug interaction studies between GRANIX and other drugs have been performed.
Drugs which may potentiate the release of neutrophils‚ such as lithium‚ should be used with caution.
Increased hematopoietic activity of the bone marrow in response to growth factor therapy has been associated with transient positive bone imaging changes. This should be considered when interpreting bone-imaging results.
Risk Summary
The limited published data on filgrastim product use during pregnancy are insufficient to inform a drug-associated risk. In animal reproduction studies, administration of tbo-filgrastim to pregnant rabbits during organogenesis resulted in increased spontaneous abortion and fetal malformations at systemic exposures 50-90 times the human exposure expected at the recommended human dose (see Data). GRANIX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population(s) are unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
Data
Animal Data
In an embryofetal developmental study, pregnant rabbits were administered subcutaneous doses of tbo-filgrastim during the period of organogenesis at 1, 10 and 100 mcg/kg/day. Increased abortions were evident in rabbits treated with tbo-filgrastim at 100 mcg/kg/day. This dose was maternally toxic as demonstrated by reduced body weight. Other embryofetal findings at this dose level consisted of post-implantation loss‚ decrease in mean live litter size and fetal weight, and fetal malformations such as malformed hind limbs and cleft palate. The dose of 100 mcg/kg/day corresponds to a systemic exposure (AUC) of approximately 50-90 times the exposures observed in patients treated with the clinical tbo-filgrastim dose of 5 mcg/kg/day.
No data are available regarding the presence of tbo-filgrastim in human milk, the effects of the drug on the breast fed infant, or the effects of the drug on milk production. Another filgrastim product was detected in human milk for up to 3 days after filgrastim administration.
The safety and effectiveness of GRANIX in pediatric patients have not been established.
Among 677 cancer patients enrolled in clinical trials of GRANIX, a total of 111 patients were 65 years of age and older. No overall differences in safety or effectiveness were observed between patients age 65 and older and younger patients.
No case of overdose has been reported.
GRANIX (tbo-filgrastim) is a non-glycosylated recombinant methionyl human granulocyte colony-stimulating growth factor (r-metHuG-CSF) manufactured by recombinant DNA technology using the bacterium strain E coli K802. It has a molecular weight of approximately 18.8 kDa and is composed of 175 amino acids. The endogenous human G-CSF is glycosylated and does not have the additional methionine amino acid residue in its NH2 terminal end.
The product is a sterile, clear, colorless, preservative-free solution containing tbo-filgrastim, glacial acetic acid, sorbitol, polysorbate 80, sodium hydroxide, and Water for Injection. The product is available in single-use prefilled syringes that contain either 300 mcg or 480 mcg of tbo-filgrastim at a fill volume of 0.5 mL or 0.8 mL, respectively. See table below for product composition of each single-use prefilled syringe.
| ||
300 mcg/0.5 mL Syringe | 480 mcg/0.8 mL Syringe | |
Tbo-filgrastim | 300 mcg | 480 mcg |
Glacial Acetic Acid | 0.3 mg | 0.48 mg |
Polysorbate 80 | 0.0275 mg | 0.044 mg |
Sorbitol | 25 mg | 40 mg |
Sodium Hydroxide | q.s. to pH 4.2 | q.s. to pH 4.2 |
Water for Injection | q.s. to 0.5 mL | q.s. to 0.8 mL |
Tbo-filgrastim is a human granulocyte colony-stimulating factor (G-CSF) produced by recombinant DNA technology. Tbo-filgrastim binds to G-CSF receptors and stimulates proliferation of neutrophils. G-CSF is known to stimulate differentiation commitment and some end-cell functional activation, which increases neutrophil counts and activity.
In the clinical trials of patients with cancer, the time to the ANCmax was between 3 to 5 days and returned to baseline by 21 days following completion of chemotherapy. In the healthy volunteer trials, doubling the tbo-filgrastim subcutaneous dose from 5 to 10 mcg/kg resulted in a 16%-19% increase in the ANCmax and a 33%-36% increase in the area under the effect curve for ANC.
Cardiac Electrophysiology
At the maximum recommended intravenous dose of 5 μg/kg, tbo-filgrastim did not prolong the QT interval to any clinically relevant extent.
In healthy subjects, the absolute bioavailability of 5 mcg/kg subcutaneous tbo-filgrastim was 33%. Increasing the dose of tbo-filgrastim from 5 to 10 mcg/kg in these healthy subjects resulted in an approximately 200% increase in both the maximum concentration (Cmax) and the area under the curve (AUC0-48h) of the drug.
In the clinical trials of patients with cancer, the AUC and Cmax were greater and more variable compared to healthy volunteers receiving the same dose of tbo-filgrastim subcutaneously. The median time to maximum concentration was between 4 to 6 hours and the median elimination half-life was between 3.2 to 3.8 hours. Accumulation was not observed after repeated dosing.
Pharmacokinetics in Specific Populations
Age: Not evaluated.
Gender: No gender-related differences were observed.
Renal Impairment: Mild renal impairment (creatinine clearance 60 - 89 mL/min) had no effect on tbo-filgrastim pharmacokinetics (N=11). The pharmacokinetic profile in patients with moderate and severe renal impairment has not been assessed.
Hepatic Impairment: The pharmacokinetic profile in patients with hepatic impairment has not been assessed.
Carcinogenicity and genetic toxicology studies have not been conducted with tbo-filgrastim.
A fertility study was not conducted with tbo-filgrastim. Toxicology studies of up to 26 weeks in rats or monkeys did not reveal findings in male or female reproductive organs that would suggest impairment of fertility.
The efficacy of GRANIX was evaluated in a multinational, multicenter, randomized and controlled Phase 3 study in 348 chemotherapy-naive patients with high-risk stage II, stage III, or stage IV breast cancer receiving doxorubicin (60 mg/m2) and docetaxel (75 mg/m2) comparing GRANIX to placebo and a non-US-approved filgrastim product as controls. The median age of the patients was 50 years (range 25 to 75 years) with 99% female and 86% Caucasian.
GRANIX, placebo, and the non-US-approved filgrastim product were administered at 5 mcg/kg subcutaneously once daily beginning one day after chemotherapy for at least five days and continued to a maximum of 14 days or until an ANC of ≥10,000 x 106/L after nadir was reached.
GRANIX was superior to placebo in duration of severe neutropenia (DSN) with a statistically significant reduction in DSN (1.1 days vs. 3.8 days, p < 0.0001).
GRANIX solution for injection is supplied as a single-dose, preservative-free clear solution, prefilled syringe of Type I glass which has a permanently attached stainless steel needle. Syringes may be supplied with or without an UltraSafe Passive® Needle Guard.
The active substance is tbo-filgrastim.
GRANIX 300 mcg/0.5 mL: Each prefilled syringe contains 300 mcg of tbo-filgrastim in 0.5 mL solution with a blue plunger in:
GRANIX 480 mcg/0.8 mL: Each prefilled syringe contains 480 mcg of tbo-filgrastim in 0.8 mL solution with a clear plunger in:
GRANIX and all its components are not made with natural rubber latex [see Dosage and Administration (2.2)].
Store GRANIX syringes in a refrigerator at 36° to 46° F (2° to 8° C). Protect from light. Within its shelf life, the product may be removed from 36° to 46° F (2° to 8° C) storage for a single period of up to 5 days between 73° to 81° F (23° to 27° C). If not used within 5 days, the product may be returned to 36° to 46° F (2° to 8° C) up to the expiration date. Dispose of syringes if stored at room temperature for more than 5 days.
Avoid shaking. The solution should be visually inspected prior to use. Only clear solutions without particles should be used. Exposure to 23° to 30° F (-1° to -5 °C) for up to 72 hours and temperatures as low as 5° to -13° F (-15 to -25° C) for up to 24 hours do not adversely affect the stability of GRANIX.
Single-dose syringe – discard unused portion. Any unused product or waste material should be disposed of in accordance with local requirements.
If GRANIX gets on the skin, wash the area with soap and water. If GRANIX gets in the eyes, thoroughly flush the exposed eye/eyes with water.
Availability of Patient Information and Instructions for Use
Advise all patients and/or caregivers to read the FDA-approved Patient Information. For patients that are candidates for self-administration, assist patients and caregivers in understanding the contents of the Patient Information as well as the GRANIX Instructions for Use that are included with the product, and give them the opportunity to ask questions prior to initiating therapy.
Patient Training
Once it is determined that a patient is an appropriate candidate for self-administration or administration by a caregiver, instruct the patient or caregivers on the proper storage, preparation, and administration technique for GRANIX. Patients should be advised not to skip or change their dose or stop taking GRANIX without talking to their healthcare provider first. Advise the patients to read the FDA-approved Patient Information and Instructions for Use for further information.
Bone Pain
Bone pain is common. Analgesics such as acetaminophen or NSAIDS may be necessary [see Adverse Reactions (6.1)].
Rupture or Enlargement of Spleen
Rupture or enlargement of the spleen may occur, which may be signaled by abdominal pain, left upper quadrant pain, or left shoulder pain. Advise patients to report onset of pain in these areas to their doctor immediately [see Warnings and Precautions (5.1)].
Dyspnea
Dyspnea with or without fever, progressing to Acute Respiratory Distress Syndrome, may occur. Advise patients to report dyspnea immediately to their doctor [see Warnings and Precautions (5.2)].
Allergic Reactions
Serious allergic reactions, including anaphylaxis, rash, and urticaria: Patients should report such reactions immediately to their doctor [see Warnings and Precautions (5.3)].
Sickle Cell Disorders
In patients with sickle cell disorders, sickle cell crisis and death has occurred. Discuss the potential risks and benefits for patients with sickle cell disorders prior to the administration of GRANIX [see Warnings and Precautions (5.4)].
Glomerulonephritis
Symptoms may include swelling of the face or ankles, dark colored urine or blood in the urine, or a decrease in urine production. Advise patients to report signs or symptoms of glomerulonephritis to their physician immediately [see Warnings and Precautions (5.5)].
Infections
GRANIX is used in circumstances where the risk of infection is increased. Patients should be alert for signs of infection such as fever, redness or swelling, and should report these findings to their doctor immediately.
Pregnancy
Inform patients not to become pregnant while receiving GRANIX. If pregnancy occurs, advise patients of the possibility of fetal harm [see Use in Specific Populations (8.1)].
Lactation
Inform lactating women that filgrastim was detected in breast milk for up to 3 days after dosing [see Use in Specific Populations (8.2)].
See FDA-Approved Patient Labeling (Patient Information) and Instructions for Use
TBO-006
©2014-2017 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved.
GRANIX is a trademark of Teva Pharmaceutical Industries Ltd.
Manufactured by:
Sicor Biotech UAB
Vilnius, Lithuania
U.S. License No. 1803
Distributed by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
Product of Israel
Revision 06/2017
GRANIX (GRAN-icks) (tbo-filgrastim) injection, for subcutaneous use |
What is GRANIX? GRANIX is a prescription medicine:
It is not known if GRANIX is safe and effective in children. |
Do not take GRANIX if you have had a serious allergic reaction to filgrastim or pegfligrastim products. |
Before you receive GRANIX, tell your healthcare provider about all of your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. |
How will I receive GRANIX?
|
What are the possible side effects of GRANIX? GRANIX can cause serious side effects, including:
Your healthcare provider may decrease your dose, temporarily stop, or permanently stop treatment with GRANIX if you have certain side effects.The most common side effect of GRANIX is bone pain. Tell your healthcare provider right way if you have any signs of infection during treatment with GRANIX such as fever, redness, or swelling. These are not all the possible side effects of GRANIX. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. |
How should I store GRANIX?
Keep GRANIX and all medicines out of the reach of children. |
General information about the safe and effective use of GRANIX Medicines are sometimes prescribed for purposes other than those listed in Patient Information leaflets. Do not use GRANIX for a condition for which it was not prescribed. Do not give GRANIX to other people, even if they have the same symptoms you have. It may harm them. You can ask your healthcare provider or pharmacist for information about GRANIX that is written for health professionals. |
What are the ingredients in GRANIX? Active ingredient: tbo-filgrastim Inactive ingredients: glacial acetic acid, sorbitol, polysorbate 80, sodium hydroxide, and Water for Injection Manufactured by: Sicor Biotech UAB Vilnius, Lithuania U.S. License No. 1803 Distributed by: Teva Pharmaceuticals USA, Inc. North Wales, PA 19454 Product of Israel
©2014-2017 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved. GRANIX is a trademark of Teva Pharmaceutical Industries Ltd. For more information, call 1-800-896-5855. |
This Patient Information has been approved by the U.S. Food and Drug Administration
Revised: 02/2017
GRANIX (GRAN-icks)
(tbo-filgrastim)
injection, for subcutaneous use
Important: Keep the GRANIX syringe out of the reach of children.
About the GRANIX syringe
Depending on the prescription that your healthcare provider gave you, you will receive a syringe that provides a dose of either 0.1mL to 0.5mL or 0.1mL to 0.8mL. If you are prescribed a dose over 0.8mL, two syringes will be required to reach your prescribed dose. Your healthcare provider will determine how many syringes and the correct dose in milliliters (mL) you will need to give based on your body weight. You should continue to give GRANIX daily until your healthcare provider informs you that your white blood cell count has returned to normal.
Make sure you understand the following:
Ifu Image 2 (Image 10)
Do not shake syringes.
Do not remove the needle cap until you are ready to inject.
Do not re-use a syringe. The syringe is for single-use only.
Your first dose of GRANIX is given at least 24 hours after you receive your chemotherapy.
Do not inject GRANIX within 24 hours before your next dose of chemotherapy.
Dosing schedule
Inject your total daily dose 1 time each day as prescribed by your healthcare provider, starting at least 24 hours (1 day) after the end of your chemotherapy cycle.
You should continue to give GRANIX daily until your white blood cell count returns to normal.
Ifu Image 3 (Image 11)
How to store your GRANIX syringes
Keep GRANIX and all medicines out of the reach of children.
Ifu Image 4 (Image 12)
Determining how many syringes you need for your daily dose
Ifu Image 5 (Image 13)
For example: If your prescribed dose is 1mL you would prepare 1 syringe with 0.8mL and a second syringe with 0.2mL.
Ifu Image 6 (Image 14)
Important: When using two syringes always adjust the first syringe to 0.8mL.
How to read the syringe markings
What the markings on the syringe mean:
The syringe is labeled in 0.1mL unit increments from 0.1mL to 0.8mL. There is a line next to each 0.1mL unit increment.
To read the dose scale always hold the syringe with the needle-end facing up so that 0.1mL is at the top and 0.8mL is at the bottom.
Ifu Image 7 (Image 15)
How to adjust the medicine level for your prescribed dose
Ifu Image 8 (Image 16)
Ifu Image 9 (Image 17)
Do not use the top of the cone or the middle or lower edges of the grey stopper to measure your dose.
Injection procedure (follow the steps below for each day of dosing)
1A Each time you inject a dose gather the following supplies:
Note: GRANIX and all of the parts of the prefilled syringe do not contain natural rubber latex.
Ifu Image 10 (Image 18)
1B Take the carton with the syringe(s) out of the refrigerator
Ifu Image 11 (Image 19)
1C Check the label and the expiration date on the side of the carton
Ifu Image 12 (Image 20)
Important: Do not inject if:
1D Remove the syringe(s) from the carton
Open the carton by breaking the tamper proof seal and lifting the lid. Remove the number of syringes required for your daily dose by grasping each at the middle of the syringe body.
After removing your required number of syringes, place the carton back in the refrigerator.
Ifu Image 13 (Image 21)
Ifu Image 14 (Image 22)
1E Look carefully at the syringe(s) and the medicine
Hold the syringe body and check to make sure it is not damaged.
Inspect the medicine in the syringe. GRANIX should be a clear liquid.
Ifu Image 15 (Image 23)
Important: Do not inject if:
1F Wait 30 minutes for the syringe(s) to warm to room temperature
Wait 30 minutes for GRANIX to naturally warm to room temperature. This will provide a more comfortable injection.
Ifu Image 16 (Image 24)
1G Wash your hands
When ready to inject, wash your hands with soap and warm water and dry thoroughly with a clean towel.
Ifu Image 17 (Image 25)
1H Choose an injection site
The recommended injection sites are:
If you are self-injecting:
Stomach-area (abdomen): Except for a 2-inch area around the navel (belly button).
Thighs: Top or middle area of thighs.
If a caregiver is injecting GRANIX for you:
Arms: Fleshy areas on upper, back part of the arm.
Upper hip or buttock: Fleshy areas around the back of the upper hips and upper sides of the buttocks.
If 2 injections will be performed, then the second injection should be at least 1 inch away from the first injection.
Ifu Image 18 (Image 26)
Do not inject into areas that are tender, red, bruised, hard, or have scars or stretch marks.
Important:
1I Clean the injection site using an alcohol swab
Allow site to dry for 5-10 seconds to avoid stinging.
If giving 2 injections, then the distance between the 2 injection sites should be at least 1 inch apart.
Ifu Image 19 (Image 27)
Do not touch or blow on site after cleaning.
2A Remove the needle cap from the syringe
Place a paper towel on the table.
To remove the needle cap, hold the body of the syringe firmly with 1 hand (with the needle facing away from you).
Pull the needle cap straight off, extending your hand away from the needle.
Ifu Image 20 (Image 28)
Note: Throw away the needle cap in a sharps container.
Do not recap the needle now or after the injection.
2B Hold the syringe upright and tap
Hold the syringe upright (needle pointing up), as shown.
Gently tap the barrel with your fingers to make sure any air bubbles rise to the top.
Ifu Image 21 (Image 29)
2C Slowly and carefully adjust the medicine level
Hold the syringe with the needle pointing up and slightly away from you, as shown. Make sure you can easily see the syringe markings and numbers.
Holding the plunger as shown, very slowly and carefully push the plunger up until the top edge of the grey rubber stopper is even with the line that corresponds to your prescribed dose.
Note:
Ifu Image 22 (Image 30)
Note: If you accidentally removed too much GRANIX, contact your healthcare provider before giving your injection.
3A Pinch skin
Ifu Image 23 (Image 31)
Use your free hand to firmly pinch the skin you previously cleaned.
Ifu Image 24 (Image 32)
3B Insert the needle at a 45 to 90 degree angle
Hold the body of the syringe between your thumb and index finger.
Use a quick motion to fully insert the needle straight into the pinched skin at a 45 to 90 degree angle.
When the needle is inserted, you can release the pinched skin.
Ifu Image 25 (Image 33)
Do not hold or push on the plunger while inserting the needle into the skin.
3C Push the plunger down injecting all of the GRANIX
Use your finger to gently push down on the plunger.
When the plunger head is as far down as it will go, all of the GRANIX has been injected. When done, gently remove the needle from the skin.
Ifu Image 26 (Image 34)
3D Dispose of used syringe
Put your used needles and syringes in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.
If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:
When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA’s website at: http://www.fda.gov/safesharpsdisposal.
Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.
3E Treat the injection site if needed and wash your hands
If you see drops of blood at the injection site, you can press a cotton ball or gauze over the injection site for several seconds to stop the bleeding.
Apply bandage, if needed.
When you are finished, wash your hands with soap and warm water and dry thoroughly with a clean towel.
Ifu Image 27 (Image 35)
If your dose is more than 0.8mL:
Ifu Image 28 (Image 36)
Ifu Image 29 (Image 37)
This Instructions for Use has been approved by the U.S. Food and Drug Administration.
Manufactured by:
Sicor Biotech UAB
Vilnius, Lithuania
U.S. License No. 1803
Distributed by:
Teva Pharmaceuticals USA, Inc.
North Wales, PA 19454
Product of Israel
Revised: 02/2017
TBOIFU-002
Teva Oncology Logo 3 (Image 38)
©2014-2017 Cephalon, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd. All rights reserved.
GRANIX is a trademark of Teva Pharmaceutical Industries Ltd.
NDC 63459-910-11
Rx only
Granix®
(tbo-filgrastim)
Injection
300 mcg/0.5 mL
For Subcutaneous Use Only
A recombinant Granulocyte Colony-Stimulating Factor
(rG-CSF) derived from E Coli
300 mcg/0.5 mL
For Healthcare Professional Use Only
1
Single-use prefilled syringe
with a safety needle guard
Discard unused portion
TEVA
Granix®
(tbo-filgrastim)
Injection
300 mcg/0.5 mL
For Subcutaneous Use Only
A recombinant Granulocyte Colony-Stimulating
Factor (rG-CSF) derived from E Coli
1
Single-use prefilled syringe
WITHOUT a safety needle guard
NDC 63459-910-17
Rx only
Discard unused portion
300 mcg/0.5 mL
TEVA
NDC 63459-912-11
Rx only
Granix®
(tbo-filgrastim)
Injection
480 mcg/0.8 mL
For Subcutaneous Use Only
A recombinant Granulocyte Colony-Stimulating Factor
(rG-CSF) derived from E Coli
480 mcg/0.8 mL
For Healthcare Professional Use Only
1
Single-use prefilled syringe
with a safety needle guard
Discard unused portion
TEVA
Granix®
(tbo-filgrastim)
Injection
480 mcg/0.8 mL
For Subcutaneous Use Only
A recombinant Granulocyte Colony-Stimulating
Factor (rG-CSF) derived from E Coli
1
Single-use prefilled syringe
WITHOUT a safety needle guard
NDC 63459-912-17
Rx only
Discard unused portion
480 mcg/0.8 mL
TEVA
* Please review the disclaimer below.
